FDA Hits Aesica Over Quality Controls, Record-Keeping Post author:Sam Post published:April 19, 2017 Post category:Drug Industry Daily The FDA has cited contract manufacturer Aesica for quality and record-keeping problems. Source: Drug Industry Daily You Might Also Like CBER’s Office of Tissues and Advanced Therapies Gets ‘Super Office’ Status, New Name September 28, 2022 CDER Outlines Its Regulatory Approach to Nanomaterials in Drug Products April 21, 2022 Congress Sends Bills Banning ‘Gag Clauses’ to President’s Desk September 27, 2018
CBER’s Office of Tissues and Advanced Therapies Gets ‘Super Office’ Status, New Name September 28, 2022